• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Bangalore , July 19

Biocon's first proprietary molecule Biomab EGFR has received the marketing approval from the Drug Controller General of India and will be launched in the second quarter of fiscal 2007-08.

The product based on monoclonal anti-bodies (M A bs), said to be a new therapy extending lifespan of cancer patients, will be first used for treating head and neck cancers and later colo-rectal, brain, breast, pancreatic and lung cancers. Biomab would be the first of the six cancer drugs it is pursuing jointly with the Cuban R&D partner, CIMAB.

The oncology segment dominated by chemo drugs is put at Rs 600 crore. Ms Kiran Mazumdar-Shaw said the M A bs that target specific tumours account for Rs 60 crore of this market.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals | Health

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Scene of blast

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line